Phase Ib/II Study in Metastatic Renal Cell Carcinoma

Total Page:16

File Type:pdf, Size:1020Kb

Phase Ib/II Study in Metastatic Renal Cell Carcinoma 1124TiP Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Julie E. Bauman,1 Simran Sindhu,2 Denise Roe,3 Nabil F. Saba,4 Jessica R. Bauman,5 Christine H. Chung,6 Jessica L. Geiger,7 Aarti Bhatia,8 Steven Wang,9 Audrey Baker,9 Shethal Bearelly,9 Carlos Caulin,1 Protul Shrikant,9 Barbara Burtness,8 and Panayiotis Savvides1 1The University of Arizona Cancer Center, Tucson, AZ, USA; 2Banner University Medical Center, Tucson, AZ, USA; 3Mel & Enid Zuckerman College of Public Health, The University of Arizona Cancer Center, Tucson, AZ, USA; 4Emory University Winship Cancer Institute, Atlanta, GA, USA; 5Fox Chase Cancer Center, Philadelphia, PA, USA; 6H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 7Cleveland Clinic, Cleveland, OH, USA; 8Yale Cancer Center, New Haven, CT, USA; 9University of Arizona Cancer Center, Phoenix, AZ, USA • Response assessment will be as follows: • History of second malignancy within 2 years before study day 1 (with the exception Background Study Hypothesis – Response and progression will be evaluated every 8 weeks using the revised Response Inclusion/Exclusion Criteria of excised and cured non-melanoma skin cancer, carcinoma in situ of breast or cervix, Evaluation Criteria in Solid Tumors (RECIST) version 1.1 superficial bladder cancer, stage I differentiated thyroid cancer that is resected or • Roughly 90% of all head and neck cancers are squamous cell carcinomas (HNSCC), • Inhibition of the HGF/c-Met pathway may overcome resistance to EGFR therapy – Measurable disease (Table 1) will be defined by the presence of ≥1 measurable lesion Key Inclusion Criteria observed, or pT1a /pT1b prostate cancer comprising <5% of resected tissue with which is the sixth leading cancer by incidence worldwide1 and provide an important clinical benefit in patients with R/M HNSCC that can be accurately measured in ≥1 dimension as ≥20 mm (for neck lymph nodes; normal prostate-specific antigen since resection, or cT1a/cT1b prostate cancer treated ≥15 mm) • Adults aged 18 years with brachytherapy or external beam radiation therapy with normal PSA since radiation) – Despite advances in multimodality therapy, 5-year overall survival (OS) is approximately • The cetuximab and ficlatuzumab combination or ficlatuzumab alone can improve 60% and has increased only incrementally in the past 2 decades2 the median PFS from the historical control of 2 months to 3.3 months (a 60% – Changes in the largest diameter (unidimensional measurement) of tumor lesions and the • Consent to a research biopsy of tumor tissue at baseline • Major surgery within 6 weeks before study day 1 improvement) in patients with R/M HNSCC shortest diameter in the case of malignant lymph nodes will be used – Patients with recurrent/metastatic (R/M) HNSCC have a particularly poor prognosis, • ECOG PS 0 or 1 at the time of informed consent • HIV-positive patients receiving combination antiretroviral therapy with a median OS of 6 to 10 months2 – Target lesions will be identified as all measurable lesions (up to a maximum of 2 per organ, and 5 lesions in total) and evaluated as complete response (CR), partial response • Measurable disease per RECIST version 1.1 criteria • Pregnant or breastfeeding women • To date, the only targeted therapy to treat HNSCC is cetuximab, an anti-epithelial Study Design (PR), PD, or stable disease (SD) • Histologically confirmed HNSCC from any primary site growth factor receptor (EGFR) monoclonal antibody (mAb)3 – Measurement of non-target lesions will not be required, but the presence or absence of • R/M disease, fulfilling ≥1 of the following criteria: – EGFR is a transmembrane glycoprotein receptor kinase (RTK) that initiates a • This study (NCT03422536) is an investigator-sponsored, randomized, noncomparative, each will be noted throughout the duration of follow-up Statistical Methods pleiotropic network of downstream signaling cascades, effecting cellular proliferation multicenter, 2-arm phase 2 trial of ficlatuzumab monotherapy and ficlatuzumab plus – Incurable disease (as assessed by surgical or radiation oncology) and angiogenesis cetuximab combination therapy in patients with R/M HNSCC after failure of cetuximab – Metastatic disease • The primary objective is to estimate PFS in both study arms compared with an historical (Figure 2) Table 1. Evaluation for patients with measurable disease control of 2 months represented by dealer’s choice chemotherapy in the phase 3 trial – Despite aberrant signaling in HNSCC, primary or acquired resistance to cetuximab is – Persistent or progressive disease following curative-intent radiation inevitable, initiating interest in understanding resistance mechanisms by which to drive (ie, target disease) of nivolumab in platinum-refractory HNSCC; both arms will be will be tested for a novel therapeutic options for this patient population Figure 2. Study design • Cetuximab resistant, fulfilling ≥1 of the following criteria: 60% increase of PFS from a median of 2 months to 3.33 months Best overall response Target Non-target New Overall – PFS will be tested using a log-rank test with 90% power while assuming a 0.10 one-sided • An established resistance mechanism to anti-EGFR therapy is activation of when confirmation – Disease persistence or recurrence within 6 months of completing definitive radiotherapy lesions lesions lesions response type 1 error rate alternative RTKs, including c-Met, the hepatocyte growth factor (HGF) receptor is required for locally advanced disease (radiation must have included concurrent cetuximab; Primary: induction chemotherapy may or may not have included cetuximab) – 66 patients (33 for ficlatuzumab, 33 for ficlatuzumab/cetuximab) with a total of 33 events 4 Ficlatuzumab 20 mg/kg Q2W – c-Met and/or HGF are overexpressed in approximately 80% of HNSCC (Figure 1) R PFS CR CR No CR ≥4 weeks confirmationa per arm will be required A – Disease progression during or within 6 months of cetuximab treatment in the R/M setting – Data have shown that HGF/c-Met inhibition may overcome resistance to anti-EGFR • R/M HNSCC N – Assuming a dropout percentage of 10%, 74 patients in total will be accrued to obtain the 5-9 D therapy in R/M HNSCC • ECOG PS 0-1 CR Non-CR/non-PD No PR – Prior cetuximab exposure (any line of therapy) necessary 66 eligible randomized patients O • Clinical resistance to M Ficlatuzumab 20 mg/kg Q2W + – Enrollment will take 24 months, with an additional follow-up of 6 months (making the study 2 Secondary: • Platinum-resistant or platinum-ineligible, fulfilling ≥1 of the following criteria: Figure 1. c-Met and HGF overexpression in HNSCC4 anti-EGFR therapy I cetuximab 500 mg/m CR Not evaluated No PR ≥4 weeks confirmationa duration approximately 2.5 years) Z toxicity, QoL, RR, OS, prognostic biomarker – Disease persistence or recurrence within 6 months of completing definitive radiotherapy for E Non-CR/non-PD/ – If both arms achieve the hypothesized PFS, the numerically superior arm will be advanced A B C assessment PR No PR locally advanced disease, where platinum chemotherapy was administered as a not evaluated to phase 3 testing 250 15 component of induction and/or concurrent systemic treatment Continuous treatment until PD P < 0.01 • PFS and OS will be estimated for each arm using a Kaplan-Meier estimates 200 Documented at least – Disease progression within 6 months of treatment with platinum chemotherapy Non-CR/non-PD/ 10 SD No SD once ≥4 weeks from 150 not evaluated • Toxicity and RR will be reported with an exact 95% CI baseline – Deemed as an unacceptable candidate for platinum chemotherapy (as assessed by 100 the local investigator) 5 • The relationship between PFS and candidate biomarkers will be assessed using Cox Frequency ECOG PS, Eastern Cooperative Oncology Group performance status; RR, response rate; PD, progressive disease; QoL, PD Any Yes or no PD HGF HGF Score IHC 50 quality of life. – Prior platinum exposure (any line of therapy) proportional hazards 0 0 – Baseline VeriStrat, HGF/c-Met dimers, and baseline pMet will be tested at Any PDb Yes or no PD No prior SD, PR, or CR • If eligible for immunotherapy, patients must have prior immunotherapy exposure Adj. Mucosa Tumor 0 50 100 150 200 • Patients will be randomized in a 1:1 ratio (ficlatuzumab/ficlatuzumab and cetuximab) and (anti-PD-1 or anti-PD-L1) α = 0.05 in order to guarantee a maximum 15% false discovery rate Tissue Type Tumor HGF IHC Score stratified by Any Any Yes PD – Prior exposure to investigational immunotherapies (including anti-CTLA-4, anti-OX40, • Other candidate biomarkers will be quantitatively measured and evaluated as predictors 250 30 – Human papillomavirus (HPV) status: HPV-positive HNSCC will be assessed by p16 status anti-CD40, anti-CD27, and anti-TNFR antibodies) is also considered acceptable of PFS and/or tumor response in generalized linear models P = 0.04 performed per standard of care at the local site; patients must meet both of the following aOnly for nonrandomized trials with response as the primary endpoint. bIn exceptional circumstances, unequivocal 200 25 – Calculated P values for testing the significance of prediction models will be adjusted for criteria: 1) either oropharynx or unknown primary site; and 2) p16+ by IHC where ≥70% progression in non-target lesions may be accepted as disease progression. • Within 28 days of registration, the following laboratory values must be measured: 20 false discovery using the Benjamini and Hochberg
Recommended publications
  • Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment
    Biomedicines 2015, 3, 149-181; doi:10.3390/biomedicines3010149 OPEN ACCESS biomedicines ISSN 2227-9059 www.mdpi.com/journal/biomedicines/ Review Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment Yilong Zhang 1,*, Rajul K. Jain 2 and Min Zhu 1 1 Department of Clinical Pharmacology, Modeling and Simulation, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA; E-Mail: minz@amgen.com 2 Kite Pharma, Inc., 2225 Colorado Avenue, Santa Monica, CA 90404, USA; E-Mail: rjain@kitepharma.com * Author to whom correspondence should be addressed; E-Mail: yilongz@amgen.com; Tel.: +1-805-447-7131; Fax: +1-805-376-1869. Academic Editor: Giulia Ricci Received: 22 January 2015 / Accepted: 3 March 2015 / Published: 19 March 2015 Abstract: The hepatocyte growth factor (HGF): MET axis is a ligand-mediated receptor tyrosine kinase pathway that is involved in multiple cellular functions, including proliferation, survival, motility, and morphogenesis. Aberrancy in the HGF/MET pathway has been reported in multiple tumor types and is associated with tumor stage and prognosis. Thus, targeting the HGF/MET pathway has become a potential therapeutic strategy in oncology development in the last two decades. A number of novel therapeutic agents—either as therapeutic proteins or small molecules that target the HGF/MET pathway—have been tested in patients with different tumor types in clinical studies. In this review, recent progress in HGF/MET pathway-targeted therapy for cancer treatment, the therapeutic potential of HGF/MET-targeted agents, and challenges in the development of such agents will be discussed. Keywords: HGF; MET; cancer treatment; new therapeutic agents; biomarker 1.
    [Show full text]
  • The Role of Biological Therapy in Metastatic Colorectal Cancer After First-Line Treatment: a Meta-Analysis of Randomised Trials
    REVIEW British Journal of Cancer (2014) 111, 1122–1131 | doi: 10.1038/bjc.2014.404 Keywords: colorectal; biological; meta-analysis The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials E Segelov1, D Chan*,2, J Shapiro3, T J Price4, C S Karapetis5, N C Tebbutt6 and N Pavlakis2 1St Vincent’s Clinical School, University of New South Wales, Sydney, NSW 2052, Australia; 2Royal North Shore Hospital, St Leonards, Sydney, NSW 2065, Australia; 3Monash University and Cabrini Hospital, Melbourne, VIC 3800, Australia; 4The Queen Elizabeth Hospital and University of Adelaide, Woodville South, SA 5011, Australia; 5Flinders University and Flinders Medical Centre, Flinders Centre for Innovation in Cancer, Bedford Park, SA, 5042, Australia and 6Austin Health, VIC 3084, Australia Purpose: Biologic agents have achieved variable results in relapsed metastatic colorectal cancer (mCRC). Systematic meta-analysis was undertaken to determine the efficacy of biological therapy. Methods: Major databases were searched for randomised studies of mCRC after first-line treatment comparing (1) standard treatment plus biologic agent with standard treatment or (2) standard treatment with biologic agent with the same treatment with different biologic agent(s). Data were extracted on study design, participants, interventions and outcomes. Study quality was assessed using the MERGE criteria. Comparable data were pooled for meta-analysis. Results: Twenty eligible studies with 8225 patients were identified. The use of any biologic therapy improved overall survival with hazard ratio (HR) 0.87 (95% confidence interval (CI) 0.82–0.91, Po0.00001), progression-free survival (PFS) with HR 0.71 (95% CI 0.67–0.74, Po0.0001) and overall response rate (ORR) with odds ratio (OR) 2.38 (95% CI 2.03–2.78, Po0.00001).
    [Show full text]
  • Targeted and Novel Therapy in Advanced Gastric Cancer Julie H
    Selim et al. Exp Hematol Oncol (2019) 8:25 https://doi.org/10.1186/s40164-019-0149-6 Experimental Hematology & Oncology REVIEW Open Access Targeted and novel therapy in advanced gastric cancer Julie H. Selim1 , Shagufta Shaheen2 , Wei‑Chun Sheu3 and Chung‑Tsen Hsueh4* Abstract The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in recent years. We have reviewed the recent data of clinical trial incorporating targeted agents, including inhibitors of angiogenesis, human epidermal growth factor receptor 2 (HER2), mesenchymal–epithelial transition, epidermal growth factor receptor, mammalian target of rapamycin, claudin‑18.2, programmed death‑1 and DNA. Addition of trastuzumab to platinum‑ based chemotherapy has become standard of care as front‑line therapy in advanced GC overexpressing HER2. In the second‑line setting, ramucirumab with paclitaxel signifcantly improves overall survival compared to paclitaxel alone. For patients with refractory disease, apatinib, nivolumab, ramucirumab and TAS‑102 have demonstrated single‑agent activity with improved overall survival compared to placebo alone. Pembrolizumab has demonstrated more than 50% response rate in microsatellite instability‑high tumors, 15% response rate in tumors expressing programmed death ligand 1, and non‑inferior outcome in frst‑line treatment compared to chemotherapy. This review summarizes the current state and progress of research on targeted therapy for advanced GC. Keywords: Gastric cancer, Targeted therapy, Human epidermal growth factor receptor 2, Programmed death‑1, Vascular endothelial growth factor receptor 2 Background GC mortality which is consistent with overall decrease in Gastric cancer (GC), including adenocarcinoma of the GC-related deaths [4]. gastroesophageal junction (GEJ) and stomach, is the ffth Tere have been several eforts to perform large-scale most common cancer and the third leading cause of can- molecular profling and classifcation of GC.
    [Show full text]
  • Therapeutic Targeting of the IGF Axis
    cells Review Therapeutic Targeting of the IGF Axis Eliot Osher and Valentine M. Macaulay * Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK * Correspondence: valentine.macaulay@oncology.ox.ac.uk; Tel.: +44-1865617337 Received: 8 July 2019; Accepted: 9 August 2019; Published: 14 August 2019 Abstract: The insulin like growth factor (IGF) axis plays a fundamental role in normal growth and development, and when deregulated makes an important contribution to disease. Here, we review the functions mediated by ligand-induced IGF axis activation, and discuss the evidence for the involvement of IGF signaling in the pathogenesis of cancer, endocrine disorders including acromegaly, diabetes and thyroid eye disease, skin diseases such as acne and psoriasis, and the frailty that accompanies aging. We discuss the use of IGF axis inhibitors, focusing on the different approaches that have been taken to develop effective and tolerable ways to block this important signaling pathway. We outline the advantages and disadvantages of each approach, and discuss progress in evaluating these agents, including factors that contributed to the failure of many of these novel therapeutics in early phase cancer trials. Finally, we summarize grounds for cautious optimism for ongoing and future studies of IGF blockade in cancer and non-malignant disorders including thyroid eye disease and aging. Keywords: IGF; type 1 IGF receptor; IGF-1R; cancer; acromegaly; ophthalmopathy; IGF inhibitor 1. Introduction Insulin like growth factors (IGFs) are small (~7.5 kDa) ligands that play a critical role in many biological processes including proliferation and protection from apoptosis and normal somatic growth and development [1]. IGFs are members of a ligand family that includes insulin, a dipeptide comprised of A and B chains linked via two disulfide bonds, with a third disulfide linkage within the A chain.
    [Show full text]
  • Correlation Between Gene Expression of IGF-1R Pathway Markers and Cetuximab Benefit in Metastatic Colorectal Cancer
    Published OnlineFirst January 31, 2012; DOI: 10.1158/1078-0432.CCR-11-1135 Clinical Cancer Predictive Biomarkers and Personalized Medicine Research Correlation between Gene Expression of IGF-1R Pathway Markers and Cetuximab Benefit in Metastatic Colorectal Cancer Fei Huang, Li-an Xu, and Shirin Khambata-Ford Abstract Purpose: This study examined potential correlations between markers related to the insulin-like growth factor-1 receptor (IGF-1R) pathway and clinical benefit from the anti–epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in metastatic colorectal cancer (mCRC). Experimental Design: Gene expression profiles for 70 pretreatment specimens from metastatic lesions of patients with chemorefractory mCRC receiving cetuximab monotherapy were analyzed using 74 predefined Gene-Chip probesets representing 33 unique IGF-1R pathway markers to determine correlations with progression-free survival (PFS) and disease control rate. Results: Higher IGF-1R, higher GRB7, and lower INSIG2 expression were associated with longer PFS with cetuximab in univariate analyses, particularly in patients with wild-type K-Ras tumors: median, 122 versus 60 days (P ¼ 0.01), 122 versus 57 days (P ¼ 0.011), and 57 versus 156 days (P < 0.0001), favoring higher IGF- 1R, higher GRB7, and lower INSIG2 expression, respectively. Lower IGF-1 expression was associated with a PFS benefit with cetuximab, whereas lower IGFBP3 and INSR expression levels showed trends for a PFS benefit. Lower INSIG2 expression (vs. higher expression) was associated with greater PFS in the high epiregulin-expressing group (P ¼ 0.001), but not in the low-expressing cohort suggesting an effect independent from the previously reported effect of epiregulin expression.
    [Show full text]
  • Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
    cancers Review Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy Laura Boyero 1 , Amparo Sánchez-Gastaldo 2, Miriam Alonso 2, 1 1,2,3, , 1,2, , José Francisco Noguera-Uclés , Sonia Molina-Pinelo * y and Reyes Bernabé-Caro * y 1 Institute of Biomedicine of Seville (IBiS) (HUVR, CSIC, Universidad de Sevilla), 41013 Seville, Spain; lboyero-ibis@us.es (L.B.); josnogucl@alum.us.es (J.F.N.-U.) 2 Medical Oncology Department, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain; amparo.sanchez.gastaldo.sspa@juntadeandalucia.es (A.S.-G.); miriam.alonso.sspa@juntadeandalucia.es (M.A.) 3 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain * Correspondence: smolina-ibis@us.es (S.M.-P.); mariar.bernabe.sspa@juntadeandalucia.es (R.B.-C.) These authors contributed equally to this work. y Received: 16 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Immuno-oncology has redefined the treatment of lung cancer, with the ultimate goal being the reactivation of the anti-tumor immune response. This has led to the development of several therapeutic strategies focused in this direction. However, a high percentage of lung cancer patients do not respond to these therapies or their responses are transient. Here, we summarized the impact of immunotherapy on lung cancer patients in the latest clinical trials conducted on this disease. As well as the mechanisms of primary and acquired resistance to immunotherapy in this disease. Abstract: After several decades without maintained responses or long-term survival of patients with lung cancer, novel therapies have emerged as a hopeful milestone in this research field.
    [Show full text]
  • Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma
    Published OnlineFirst February 15, 2018; DOI: 10.1158/2159-8290.CD-17-1260 RESEARCH ARTICLE Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR -Amplifi ed Gastroesophageal Adenocarcinoma Steven B. Maron 1 , Lindsay Alpert 2 , Heewon A. Kwak 2 , Samantha Lomnicki 1 , Leah Chase 1 , David Xu 1 , Emily O’Day1 , Rebecca J. Nagy 3 , Richard B. Lanman 3 , Fabiola Cecchi 4 , Todd Hembrough 4 , Alexa Schrock 5 , John Hart2 , Shu-Yuan Xiao 2 , Namrata Setia 2 , and Daniel V.T. Catenacci 1 ABSTRACT Previous anti-EGFR trials in unselected patients with gastroesophageal adeno- carcinoma (GEA) were resoundingly negative. We identifi ed EGFR amplifi cation in 5% (19/363) of patients at the University of Chicago, including 6% (8/140) who were prospectively screened with intention-to-treat using anti-EGFR therapy. Seven patients received ≥1 dose of treat- ment: three fi rst-line FOLFOX plus ABT-806, one second-line FOLFIRI plus cetuximab, and three third/ fourth-line cetuximab alone. Treatment achieved objective response in 58% (4/7) and disease control in 100% (7/7) with a median progression-free survival of 10 months. Pretreatment and posttreatment tumor next-generation sequencing (NGS), serial plasma circulating tumor DNA (ctDNA) NGS, and tumor IHC/FISH for EGFR revealed preexisting and/or acquired genomic events, including EGFR- negative clones, PTEN deletion, KRAS amplifi cation/mutation,NRAS, MYC , and HER2 amplifi cation, andGNAS mutations serving as mechanisms of resistance. Two evaluable patients demonstrated interval increase of CD3 + infi ltrate, including one who demonstrated increased NKp46+ , and PD-L1 IHC expression from baseline, suggesting an immune therapeutic mechanism of action.
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • Phase I Study of the Anti-HGF Monoclonal Antibody, Ficlatuzumab, and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer Abstract 6038 Julie E
    Phase I study of the anti-HGF monoclonal antibody, ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic head and neck cancer Abstract 6038 Julie E. Bauman, Umamaheswar Duvvuri, Robert L. Ferris, James Ohr, William E. Gooding, Seungwon Kim, Jonas T. Johnson, Jennifer R. Grandis, and Laura P. Stabile University of Arizona Cancer Center, Tucson, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; University of California San Francisco, San Francisco, CA BACKGROUND METHODS DEFINITION OF DOSE LIMITING TOXICITY RESULTS BIOMARKERS Background: Cetuximab, an anti-EGFR monoclonal antibody, Study Design: Narayana k-in-a-row adaptive phase I design with • Any ≥ Grade 3 non hematologic toxicity except the following • From Sept 2015-June 2016, 12 patients enrolled and were Waterfall Plot: Best Response by Veristrat Status is approved for patients with recurrent/metastatic (R/M) head k set to 2 for a target DLT rate of ≤ 33%. If 8 patients are treated grade 3 toxicities: rash; infusion reaction; nausea, vomiting or treated (3 at dose tier 1; 9 at dose tier 2). 60 diarrhea lasting < 48 hours; isolated AST or ALT elevation; and neck squamous cell carcinoma (HNSCC) but only a without DLT (2+6 on tiers 1 and 3), the upper 90% confidence • No DLTs were observed at any dose tier. 40 Veristrat Poor minority benefit. Median progression-free survival (PFS) and bound for the estimated DLT rate at dose tier 2 is 0.32. asymptomatic electrolyte abnormality Veristrat Good • The RP2D is ficlatuzumab 20 mg/kg and cetuximab 500 overall response rate (ORR) for cetuximab monotherapy are 2.3 • Grade 3 neutropenia with fever 20 PD Key Eligibility Criteria mg/m2 every 2 weeks.
    [Show full text]
  • An Anti-Hepatocyte Growth Factor Monoclonal Antibody, In
    Phase 1b Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC Eng-Huat Tan, 1 Keunchil Park, 2 Wan-Teck Lim, 1 Myung-Ju Ahn, 2 Quan-Sing Ng, 1 Jin Seok Ahn, 2 Daniel Shao-Weng Tan, 1 Jong-Mu Sun, 2 Jaroslaw Jac, 3 May Han, 3 Marc Credi, 3 Francis C. Payumo, 3 Krista McKee, 3 Wei Yin, 3 Pankaj Bhargava, 3,4 William Slichenmyer 3 1National Cancer Centre, Singapore; 2Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; 3AVEO Pharmaceuticals, Inc., Cambridge, MA, USA; 4Dana-Farber Cancer Institute, Boston, MA, USA. Safety and Tolerability Pharmacokinetics ● The half-life (t 1/2 ) was approximately 11 to 23 days after the first dose, in the Background Methods range expected for humanized monoclonal IgG antibodies ( Table 5 )8 Conclusions ● The most commonly reported adverse event was dermatitis acneiform (67%), ● Concentration-time profiles of ficlatuzumab and gefitinib are shown in Figure 2 ● The t was longer (32 days) after chronic dosing, indicating a likely decrease ● Ficlatuzumab (AV-299) is a highly potent humanized IgG1 ␬ anti-hepatocyte followed by cough (53%), decreased appetite (47%), and diarrhea (40%) and Figure 3 , respectively 1/2 in drug elimination possibly due to gradual saturation of HGF increase after ● The combination of ficlatuzumab and gefitinib was well growth factor (HGF) monoclonal antibody that Key Eligibility Criteria (Table 2 ) Cycle 1 as a result of ficlatuzumab treatment 7 tolerated – Neutralizes several important biological activities of HGF, such as Inclusion criteria Figure 2.
    [Show full text]
  • Progress in Pancreatic Ductal Adenocarcinoma (PDAC) Research Working Group (PDAC Progress Working Group)
    National Cancer Institute Clinical Trials and Translational Research Advisory Committee (CTAC) Progress in Pancreatic Ductal Adenocarcinoma (PDAC) Research Working Group (PDAC Progress Working Group) Working Group Report March 6, 2019 The report was accepted at the March 6, 2019 CTAC Meeting ______________________________________________________________________________________________________ PDAC Progress WG Report: Accepted by the Clinical Trials and Translational Research Advisory Committee on March 6, 2019 Page 1 TABLE OF CONTENTS Page National Cancer Institute Clinical Trials and Translational Research Advisory Committee (CTAC) Progress in Pancreatic Ductal Adenocarcinoma (PDAC) Research 3 Working Group (PDAC Progress Working Group) Report Appendix 1: Progress in Pancreatic Ductal Adenocarcinoma (PDAC) Research 16 Working Group (PDAC Progress WG) 2018 Roster Appendix 2: Funded Project Summary FY 2015 – FY 2017 • NIH PDAC Funded Projects, Initiative 1: Understanding the 18 Biological Relationship Between PDAC and Diabetes Mellitus • NIH PDAC Funded Projects, Initiative 2: Evaluating Longitudinal Screening Protocols, for Biomarkers for Earl Detection of PDAC 20 and its Precursors • NIH PDAC Funded Projects, Initiative 3: Study New Therapeutic 28 Strategies in Immunotherapy • NIH PDAC Funded Projects, Initiative 4: Developing New Treatment Approaches that Interfere with RAS Oncogene- 33 Dependent Signaling Pathways • NIH PDAC Funded Projects, No Related to the Framework t 38 Initiatives Appendix 3: PDAC Publications Supported by Grants
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]